Olema (OLMA) director granted 29,500 stock options at $9.51 exercise price

Rhea-AI Filing Summary

Olema Pharmaceuticals director Raman Prakash received a stock option grant for 29,500 shares of common stock. The option has an exercise price of $9.51 per share and expires on June 18, 2036. It was awarded as compensation rather than purchased on the open market.

The 29,500 underlying shares vest in 12 equal monthly installments starting on June 18, 2026, as long as Prakash continues in service through each vesting date. Any unvested portion will fully vest on the date of Olema’s next annual stockholder meeting if it is not already fully vested and he remains in service through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Raman Prakash

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	29,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 29,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 29,500 options Exercise price: $9.51 per share Underlying shares: 29,500 shares +3 more

6 metrics

Option grant size 29,500 options Stock Option (right to buy) granted to director Raman Prakash

Exercise price $9.51 per share Conversion or exercise price of granted stock options

Underlying shares 29,500 shares Common Stock underlying the stock option grant

Expiration date June 18, 2036 Stock option expiration for the grant

Post-grant option holdings 29,500 options Total derivative securities following the reported transaction

Monthly vesting schedule 12 monthly installments Vesting measured from June 18, 2026 subject to continuous service

Key Terms

Stock Option (right to buy), exercise price, vest, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 9.5100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The shares subject to the option vest in a series of 12 successive equal monthly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"expiration_date: 2036-06-18T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous service financial

"subject to the Reporting Person's continuous service through each applicable vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:24 PM Accepted by SEC EDGAR 06/23/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raman Prakash

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN STREET

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.51	06/18/2026		A		29,500		(1)	06/18/2036	Common Stock	29,500	$0	29,500	D

Explanation of Responses:

1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Olema Pharmaceuticals (OLMA) report for Raman Prakash?

Olema reported that director Raman Prakash received a grant of stock options for 29,500 shares of common stock. This was a compensation-related award, not an open-market purchase, and gives him the right to buy shares at a fixed exercise price.

How many Olema Pharmaceuticals (OLMA) shares are covered by Raman Prakash’s new options?

The option grant covers 29,500 underlying shares of common stock. These options give Prakash the right to buy up to 29,500 Olema shares at the specified exercise price if and when the options vest and are exercised.

What is the exercise price of Raman Prakash’s Olema Pharmaceuticals (OLMA) stock options?

The stock options granted to Raman Prakash have an exercise price of $9.51 per share. This means he can buy Olema common stock at $9.51 for each optioned share once those options have vested and before they expire.

When do Raman Prakash’s Olema Pharmaceuticals (OLMA) options vest?

The options vest in 12 equal monthly installments starting on June 18, 2026, subject to his continuous service. Any portion not vested by the next annual stockholder meeting will fully vest on that date, provided he remains in service through that vesting date.

When do Raman Prakash’s Olema Pharmaceuticals (OLMA) stock options expire?

The option award to Raman Prakash expires on June 18, 2036. He must exercise any vested options before this expiration date if he wants to purchase Olema common shares at the $9.51 exercise price provided by the grant.

Is Raman Prakash’s Olema Pharmaceuticals (OLMA) Form 4 a stock purchase or a grant?

The Form 4 shows a grant or award acquisition of stock options, coded as transaction type “A”. This reflects compensation in the form of options, not an open-market stock purchase or sale by Prakash in Olema’s common stock.